From somatostatin to octreotide LAR: evolution of a somatostatin analogue

Author： Anthony Lowell   Freda Pamela U.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.12, 2009-12, pp. : 2989-2999

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pituitary apoplexy after somatostatin analogue administration: coincidental or causative?

By  

CLINICAL ENDOCRINOLOGY, Vol. 81, Iss. 3, 2014-09 ,pp. : 471-473

John Wiley & Sons Inc

Access to resources Recommend Favorite

Synthetic Somatostatin Analog (Octreotide) Suppresses Daytime Growth Hormone Secretion Equivalently in Young and Older Men: Preserved Pituitary Responsiveness to Somatostatin's Inhibition in Aging

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 47, Iss. 12, 1999-12 ,pp. : 1422-1424

John Wiley & Sons Inc

Access to resources Recommend Favorite

Different Response to the Long-Acting Somatostatin Analogues Lanreotide and Octreotide in a Patient with a Malignant Carcinoid

By  

Oncology, Vol. 60, Iss. 2, 2001-02 ,pp. : 141-145

Karger

Access to resources Recommend Favorite

68Ga‐somatostatin analogue PET‐CT: Analysis of costs and benefits in a public hospital setting

By  

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, Vol. 62, Iss. 1, 2018-02 ,pp. : 57-63

John Wiley & Sons Inc

Access to resources Recommend Favorite

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF‐1 suppression to octreotide LAR in healthy volunteers

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 3, 2015-09 ,pp. : 460-472

John Wiley & Sons Inc

Access to resources Recommend Favorite